Financings in Brief: Datascope
This article was originally published in The Gray Sheet
Executive Summary
Datascope: Plans to buy back "up to $20 mil." of its common stock "from time to time, subject to market conditions and other relevant factors affecting the company." Datascope, which currently has approximately 16.1 mil. outstanding shares, says initiating the buyback "reflects the company's long-term view of its prospects." In an April 25 earnings release, the Montvale, New Jersey-based company projected that its near-term results "are likely to be below its earlier expectations" due to "competitive pressures," as well as increasing research and development costs in its patient monitoring division...
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.